Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme

Overview of attention for article published in Cancer Immunology, Immunotherapy, April 2013

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 6,767 followers.

RT @SympoSkinCancer: Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilim... #mdart #md http://t.co/SQDEwAGZPV

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilim... #mdart #md http://t.co/TuVqowUKxo

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilim... #mdart #md http://t.co/wCv0STng2i

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilim... #mdart #md http://t.co/SQDEwAGZPV

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilim... #mdart #md http://t.co/e21z7K2p1g

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilim... #mdart #md http://t.co/ZCqvwI24cx